Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
Lanreotide Depot/Autogel for Symptomatic Control of Carcinoid Syndrome (CS) in Patients With Neuroendocrine Tumors (NETs) Previously Responsive to Octreotide: Subanalysis of Patient-Reported Symptoms From the Phase 3 ELECT Study Pommier, R. F., Fisher, G. A., Wolin, E. M., Liyanage, N., Lowenthal, S., Mirakhur, B., Shaheen, M., Vinik, A. I. LIPPINCOTT WILLIAMS & WILKINS. 2018: 352
View details for Web of Science ID 000426086300089